Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Metastatic × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 293 Uterine Cervical Neoplasms 115 Endometrial Neoplasms 96 Breast Neoplasms 86 Carcinoma, Non-Small-Cell Lung 79 Fallopian Tube Neoplasms 72 Colorectal Neoplasms 64 Carcinoma, Ovarian Epithelial 62 Pancreatic Neoplasms 54 Neoplasms 53 Stomach Neoplasms 52 Melanoma 51 Triple Negative Breast Neoplasms 41 Squamous Cell Carcinoma of Head and Neck 41 Neoplasm Metastasis 40 Prostatic Neoplasms 36 Head and Neck Neoplasms 36 Esophageal Neoplasms 36 Lung Neoplasms 34 Urinary Bladder Neoplasms 31 Carcinoma, Renal Cell 27 Recurrence 23 Small Cell Lung Carcinoma 22 Sarcoma 22 Carcinoma, Hepatocellular 20 Colonic Neoplasms 19 Carcinoma, Transitional Cell 18 Mesothelioma 15 Lymphoma 15 Peritoneal Neoplasms 14

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡